Umbilical Cord Blood as an Alternate Donor Sources for High Risk Elderly Patients Undergoing Allogeneic Stem Cell Transplantation for Hematological Malignancies
OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 7 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).
Allogeneic Stem Cell Transplantation
Submission Deadline: January 30, 2021 (Open) Submit Now
Martin Guimond, PhD
Associate Professor, Department of Microbiology, Infection, and Immunology, University of Montreal, Montreal, Quebec, Canada; Research Center, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
Research Interests: T Lymphocytes; immunomodulation; allogeneic stem cell transplatation; stem cell transplantation; graft-versus-host disease; immunology
About this topic
In 1980, the New England Journal of Medicine published the first successful unrelated bone marrow transplantation to treat acute leukemia. Since then, the field of stem cell transplantation has evolved considerably. Today, allogeneic-SCT remains the only curative treatment for several patients with high risk refractory hematologic cancers. Recently, clinical trials were developed to evaluate the use of Allogeneic Stem Cell transplantation to treat/cure solid tumors. This Special Issue will cover new developments in the field of Allogeneic Stem Cell Transplantation including new procedures in Allogeneic Stem cell Transplantation, conditioning regiments, stem cell source, strategies to reduce/control acute or chronic graft-versus-host disease (T cell depletion, mesenchymal stem cells, suicide genes…), modulation of graft-versus leukemia (cytokines, CAR-T cells), management of infectious complications, strategies to improve immune reconstitution, in vitro and in vivo studies, animal models, and clinical trials on Allogeneic Stem Cell Transplantation. Original research papers, mini and full reviews and commentaries are all welcome. There is no restriction on the length of the manuscripts. Peer-review is commissioned immediately upon receipt of the manuscript.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.